
#48 - Omri Amirav-Drory : The End of Scarcity: If AI Can Do Every Job, What’s Left for Us?
Shownotes
We spend a lot of time asking what AI can do. Write software. Analyse a company. Design an experiment.
A harder question follows: if those capabilities become widely available, where does value move?
That was the starting point for our conversation with Omri Amirav-Drory, a scientist, founder, and general partner who leads NFX Bio. Before becoming an investor, he founded Genome Compiler, which was acquired by Twist Bioscience.
We connected through his essay, The Case for Venture Capital in the Age of Superintelligence. It asks what investors should fund when AI might eventually outperform the companies—and investors—they back. nfx.com
Omri is refreshingly willing to include himself in that question.
“Everybody has their own excuse why their job is special.”
His answer takes us through robotics, biology, longevity, and the future of work. The thread connecting them is simple: as one capability becomes abundant, the opportunity moves towards whatever still constrains progress.
Three ideas to take into the episode:
- Faster intelligence still has to work through the physical world.
- Biology could become a much larger frontier for company building.
- Abundance changes what is valuable—and what gives people meaning.